What podcasts say about Johnson & Johnson
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Johnson & Johnson
5 statements · 4 positive · 1 negative
Johnson & Johnson agreed to commit $5.5 billion toward resolving talc litigation.
“Johnson Johnson says it has agreed to a $5.5 billion commitment to resolve litigation related to claims that its talc products caused ovarian cancer.”
Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital RalliesListen at 2:33
If signed, the Johnson & Johnson agreement will help close the long-running litigation issue.
“But but if it's signed, it will help close an issue that's been ongoing for at least 15 years.”
Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital RalliesListen at 2:50
Johnson & Johnson shares fell despite earnings beats and modestly raised 2026 guidance.
“Johnson and Johnson shares trading under ticker JNJ are down almost 2% in the premarket after the pharma company beat second quarter top and bottom line estimates and the company modestly raised its 2026 sales and profit guidance.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:00
Johnson & Johnson’s earnings beat was driven by drug growth in several therapeutic areas.
“The company's beat was driven by growth for its of cancer, inflammatory diseases and treatment resistant depression drugs.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:35
Johnson & Johnson’s results suggest drug makers are thriving despite regulatory and pricing pressures.
“This company is suggesting drug makers are thriving despite some recent turmoil at the FDA and some deals with the White House to lower net prices on some medicines.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:55
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.